B-cell depletion in SLE: clinical and trial experience with rituximab and …7thSpace Interactive (press release)In recent years there have been many publications regarding the experience in SLE of B-cell depletion utilising rituximab, an anti-CD20 mAb…
Combination of two antibodies prevents growth and spread of triple-negative …News-Medical.netIn a study published recently in the Proceedings of the National Academy of Sciences, Weizmann Institute researchers propose a potential solution: to simulta…
|
Clinical Notes: Users Deem E-Cigs Safer
MedPage Today In comments made to industry analysts at a meeting, the company’s CEO Robert Bradway said Amgen would be launching biosimilar versions of bevacizumab (Avastin), adalimumab (Humira), infliximab (Remicade), trastuzumab (Herceptin), rituximab … |
MS Patient Dies From Anti-Drug AntibodiesMedPage TodayPoint out that the authors recommend that repeated moderate to severe infusion reactions in the beginning of natalizumab treatment should prompt the cessation of treatment and assessment for the dev…
|
Two Antibodies Are Better Than One
HealthCanal.com Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells – receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to … |
|
8 Biotech Growth Names: Greg Wade
Seeking Alpha Is this drug going to be tested in all of the old indications that rituximab (Rituxan; Genentech USA Inc./Biogen Idec Inc.) was developed for originally? GW: It has shown some activity in a number of them. I don’t actually have a breakdown of where … |
Antitope inks research pact with Eden Biodesign for developing therapeutic …pharmabiz.comAntitope Ltd., a biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity,…
ImmunoReagents Enters Distributorship Agreement with Abyntek Biopharma …PR.com (press release)Raleigh, NC, February 08, 2013 –(PR.com)– ImmunoReagents, a manufacturer of high quality polyclonal antibodies and reagents used by researchers, pharmaceu…
|
Eight Biotech Growth Names: Greg Wade
Jutia Group Is this drug going to be tested in all of the old indications that rituximab (Rituxan; Genentech USA Inc./Biogen Idec Inc. (BIBB:NASDAQ)) was developed for originally? GW: It has shown some activity in a number of them. I don’t actually have a … |
HealioLenalidomide, rituximab combination shows promise in CLLHealioThe study regimen included rituximab 375 mg/m2 IV administered weekly during cycle one and on day 1 of cycles three to 12. Oral lenalidomide was initiated on day 9 of cycle one at 10 m…